[{"orgOrder":0,"company":"Advent","sponsor":"The Jenner Institute, Oxford University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Advent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advent \/ The Jenner Institute, Oxford University","highestDevelopmentStatusID":"6","companyTruncated":"Advent \/ The Jenner Institute, Oxford University"},{"orgOrder":0,"company":"IGEA Clinical Biophysics","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"CORVax12","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IGEA Clinical Biophysics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGEA Clinical Biophysics \/ OncoSec Immunotherapies","highestDevelopmentStatusID":"6","companyTruncated":"IGEA Clinical Biophysics \/ OncoSec Immunotherapies"},{"orgOrder":0,"company":"ReiThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GRAd-COV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReiThera \/ Inapplicable"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.

                          Product Name : Teicoplanin Sandoz

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 18, 2021

                          Lead Product(s) : Teicoplanin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : U.S. Food and Drug Administration (FDA) has cleared the Cliniporator platform for use in the upcoming Phase 1 trial to be held at Providence Health investigating CORVax12, the Company's DNA-encodable vaccine candidate for COVID-19.

                          Product Name : CORVax12

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 24, 2020

                          Lead Product(s) : CORVax12

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : OncoSec Immunotherapies

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The Jenner Institute at the University of Oxford has agreed a contract with Advent Srl, to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.

                          Product Name : ChAdOx1

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 02, 2020

                          Lead Product(s) : ChAdOx1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : The Jenner Institute, Oxford University

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Neupharma is developing an inhaled formulation of teicoplanin, a glycopeptide antibiotic, for the treatment of methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis.

                          Product Name : Teicoplanin Sandoz

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 28, 2020

                          Lead Product(s) : Teicoplanin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The Phase 1 clinical trial is evaluating the safety and immunogenicity of GRAd-COV2 in 90 healthy volunteers with an objective to select a vaccine dose for further investigation in a Phase 2/3 trial.

                          Product Name : GRAd-COV2

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 24, 2020

                          Lead Product(s) : GRAd-COV2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank